NIH has launched a major new initiative called the Environmental Influences on Child Health Outcomes (ECHO) program to investigate environmental exposures on child health and development. An important component of the program will be the IDeA States Pediatric Clinical Trials Network (ISPCTN), which the Eunice Kennedy Shriver National Institute of Child Health and Human Development is leading in collaboration with us.
The ISPCTN will give medically underserved and rural populations access to state-of-the-art pediatric clinical trials. The network’s clinical trials sites, which will be located in states eligible for funding through our Institutional Development Award (IDeA) program, will receive support for the development of appropriate research infrastructure as well as supervised professional development in all aspects of clinical trials research and implementation. We expect the ISPCTN to help strengthen pediatric research opportunities and capacity in IDeA states, which historically have not received extensive NIH funding.
If you’re in an IDeA-eligible state (including Puerto Rico), we encourage you to apply to either or both of the ISPCTN FOAs:
Applications proposing studies on all pediatric diseases and conditions will be considered, but priority will be given to those on the focus areas and core elements of the ECHO program, which include upper and lower airway disease; obesity; pre-, peri-, and postnatal outcomes; and neurodevelopment. The application deadline for both announcements is April 15, 2016, with optional letters of intent due by March 15, 2016.
For more information about the ECHO program and its various FOAs, you can participate in webinars scheduled for January 14, 2016, and February 1, 2016, or contact one of us (email@example.com, firstname.lastname@example.org).
The September 9 receipt date for the Maximizing Investigators’ Research Award (MIRA) for New and Early Stage Investigators (R35) is just one week away! We recommend that applicants submit a few days early to give themselves time to check that their applications as received by NIH are complete and correct.
A few points of clarification about the deadline:
- If you’re planning to submit an AIDS or AIDS-related application for the later receipt date of November 19, 2015, please contact me immediately to discuss whether the MIRA grant mechanism is appropriate. It may not be when only part of the research is AIDS-related.
- The expiration date for the funding opportunity announcement is listed as November 20, 2015. This is not the receipt date. Do not be misled by this or any reference to a closing date on forms downloaded from Grants.gov.
As we enter the second year of the NIH Common Fund Glycoscience program to develop accessible tools for carbohydrate research, we encourage those who are new to carbohydrate chemistry and biology to bring their fresh perspectives to bear on difficult challenges in this field by applying through one of the following funding opportunity announcements (FOAs). While we continue to welcome applications from carbohydrate scientists, we hope to see new ideas from synthetic chemists and technology developers from other fields. Our goal is to enable researchers in all biomedical fields to study the roles of carbohydrates in health and disease, so approaches from outside the established glycoscience community are of particular interest.
UPDATE: Due to technical difficulties, the MIRA webinar was not recorded. We have posted the slides on the MIRA Web page, where we’ll also post a summary of the webinar questions and answers.
NIGMS Director Jon Lorsch and I will field questions about the recently announced Maximizing Investigators’ Research Award (MIRA) for New and Early Stage Investigators (R35) during a webinar on Tuesday, June 30, from 1-2 p.m. EDT. Participants will be able to submit questions using the chat feature. We’ll post the archived webinar and slides on the MIRA Web page.
The most common questions we’re getting about the new MIRA funding opportunity announcement (FOA) have concerned eligibility, so we created a new flowchart to help determine this. Another common question has related to research areas appropriate for support by a MIRA. These and other topics are covered in our answers to frequently asked questions about the second MIRA FOA.
If you have colleagues who may be eligible to apply but may not know about the FOA or may have questions about it, please share this post with them.
As with the first MIRA FOA, this competition is an experiment and is intentionally limited to a small group of eligible applicants. If the pilot is successful, we plan to issue future FOAs covering additional groups of investigators.
For more information about the MIRA program, e-mail me or call me at 301-594-0828.
We have just expanded the pilot of our Maximizing Investigators’ Research Award (MIRA) to include new and early stage investigators. The application due date is September 9, and we request—but do not require—letters of intent by August 9.
MIRA supports investigators’ overall research programs through a single, unified grant rather than individual project grants. The goals include increasing investigators’ funding stability, ability to take on ambitious challenges and approach problems creatively, and flexibility to follow important new research directions as opportunities arise.
Awards will provide all of the support from NIGMS for research related to its mission in an investigator’s laboratory. [Editor’s note: Awards will be for 5 years, similar to the current average length of an NIGMS R01 award to new investigators.]
As I wrote in a previous post on the Pharmacogenomics Research Network (PGRN), we have been transitioning our support of pharmacogenomics research from set-aside funding to regular competition with other scientific areas. This is part of the Institute’s efforts to bolster support for investigator-initiated research. We’ll now fund pharmacogenomics research primarily through regular research grant mechanisms, such as R01s or well-justified P01s.
To learn more about how pharmacogenomics-related applications fare in review, our Office of Program Planning, Analysis, and Evaluation conducted an analysis of NIH-wide pharmacogenomics-related applications assigned to Center for Scientific Review study sections. The analysis showed that these applications have comparable success in the review and award processes as applications in other scientific fields. Even so, I still recommend that applicants include a cover letter describing the kinds of expertise they believe are needed for an appropriate review. This can be particularly beneficial for a multidisciplinary research area like pharmacogenomics.
You may be interested in these recent funding opportunity announcements:
Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32)
Purpose: Prepare predoctoral students for independent research careers in the neurosciences
Letter of intent due dates: 30 days prior to the application due date
Application due dates: June 10, 2015; May 25, 2016; May 25, 2017
NIGMS contact: Stephen Korn, 301-496-4188
Availability of Administrative Supplements to NIGMS Predoctoral Training Grants (Admin Supp)
Purpose: Request supplemental funds to existing predoctoral training grants to develop and implement curricular activities to enhance rigor and reproducibility in research and broaden training activities to better prepare students for a variety of scientific career paths
Application due date: April 30, 2015
NIGMS contact: Shiva Singh, 301-594-3900
While it is well recognized that an individual’s microbiome has a substantial influence on health, fundamental knowledge gaps remain regarding host-microbial interactions, especially those involving the effects of probiotic and prebiotic products. To stimulate research in this area, NIGMS is participating with a number of other NIH institutes and centers in a new funding opportunity announcement (FOA), Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01).
We are looking for biochemists, chemists, bioengineers, systems biologists and others to define biochemical pathways, small molecules and biologics in host-microbial interactions. We are particularly interested in applications from interdisciplinary teams that propose to provide a functional and mechanistic picture of host-microbial ecosystems. This includes an understanding of host-probiotic-microbial interactions and the effect of exogenous molecules such as prebiotics on these interactions. We also encourage the development of computational models, tools and technologies that enable the prediction, identification, quantification and characterization of host-microbial dynamics as well as the development of tractable host-microbial systems.
This FOA is a program announcement with no set-aside funds. Standard R01 due dates apply, so the first receipt date is June 5. Although a letter of intent is not required, we recommend that you contact us (e-mail Barbara in the Division of Pharmacology, Physiology, and Biological Chemistry or e-mail Darren in the Division of Genetics and Developmental Biology) to discuss your potential proposal and NIGMS-specific FOA guidelines.
NIGMS Director Jon Lorsch and I will field your questions about the recently announced Maximizing Investigators’ Research Award (MIRA) (R35) during a webinar on Thursday, Feb. 19, from 2-3 p.m. EST. You’ll be able to access the webinar at https://webmeeting.nih.gov/nigmsmira/. During the event, you can submit questions by calling 301-451-4301 or e-mailing me. You also can send questions to me ahead of time.
Since announcing this new funding opportunity, we’ve received many inquiries. The most common questions have concerned eligibility, so we created a flowchart to help you determine this. Our MIRA Answers to Frequently Asked Questions offer additional details about eligibility, the submission and review processes, award administration and other aspects of the program. The earliest start date is April 2016, not December 2016 as originally indicated in the funding opportunity announcement.
As stated in earlier posts, this first MIRA competition is an experiment and is intentionally limited to a small group of eligible applicants. If this pilot is successful, we plan to issue future funding opportunity announcements covering additional groups of investigators.
UPDATE: The Maximizing Investigators’ Research Award (MIRA) (R35) Web page also includes links to the MIRA webinar and slides, MIRA-specific instructions for listing current and pending support, and a sample NIH biosketch.